VG

Veronica Gambillara Fonck

Life Science Entrepreneur, Advisor and Board member

Zurich, Zurich

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Partner

    2022

2021 - 2022

  • CEO-and Co-Founder

    2021 - 2022

  • CEO-Co-founder

    2015 - 2021

    LimmaTech Biologics is a biotech Company based on innovative platform to make bioconjugate. Former GlycoVaxyn, acquired by GSK in 2015, LimmaTech maintains a close relationship with GSK for the development of novel vaccines . Moreover, with the deep in-house expertise of glycoconjugation is also working in the therapeutic field.

2009 - 2015

  • Executive Director, Clinical and Regulatory Affairs

    2012 - 2015

    • Overall responsibility for designing and managing company’s drug development strategy and operations •Assessed and evaluated the early stage product portfolio, streamlined preclinical development and prioritised clinical development •Built and developed an effective operational clinical team, created partnerships with relevant academic institutions. Selected participants, built agenda and managed the meetings of the International Advisory Board, international Expert- and Investigator’s groups •Responsible for the regulatory submission process (IND/IMPD submission to FDA/EMEA and Swissmedic)

  • Director Business Development

    2011 - 2012

  • Director Clinical and Regulatory Affairs

    2009 - 2011

2007 - 2009

  • Manager Clinical Affairs

    2007 - 2009

    Design, Initiate and Conduct pre and post-market studies in Europe and US for medical device.

2006 - 2007

  • Project Manager

    2006 - 2007

  • Research Assistant

    2001 - 2005